IRIS
PUCCINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.888
NA - Nord America 1.757
SA - Sud America 443
EU - Europa 436
Continente sconosciuto - Info sul continente non disponibili 102
AF - Africa 50
Totale 4.676
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.664
SG - Singapore 999
CN - Cina 397
BR - Brasile 345
IT - Italia 208
VN - Vietnam 195
HK - Hong Kong 84
FR - Francia 46
CA - Canada 45
IN - India 45
DE - Germania 37
BD - Bangladesh 31
AR - Argentina 30
GB - Regno Unito 27
MX - Messico 25
EC - Ecuador 20
ID - Indonesia 20
AT - Austria 18
TR - Turchia 17
CL - Cile 14
PL - Polonia 13
CO - Colombia 12
ES - Italia 12
JP - Giappone 12
MA - Marocco 12
FI - Finlandia 11
IQ - Iraq 11
MY - Malesia 11
NL - Olanda 10
SE - Svezia 10
ZA - Sudafrica 10
JM - Giamaica 9
RU - Federazione Russa 9
EG - Egitto 8
SA - Arabia Saudita 8
VE - Venezuela 8
PH - Filippine 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
HN - Honduras 5
KZ - Kazakistan 5
LT - Lituania 5
PY - Paraguay 5
UA - Ucraina 5
KE - Kenya 4
NP - Nepal 4
TN - Tunisia 4
CY - Cipro 3
PK - Pakistan 3
QA - Qatar 3
RS - Serbia 3
UZ - Uzbekistan 3
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
TH - Thailandia 2
ZM - Zambia 2
AD - Andorra 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
IL - Israele 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 4.572
Salva come PNG Salva come JPEG
Città #
Dallas 513
Singapore 406
Ashburn 229
San Jose 179
Beijing 165
The Dalles 151
Ho Chi Minh City 84
Hong Kong 84
Milan 69
Santa Clara 63
Los Angeles 59
New York 46
Buffalo 34
Hanoi 32
São Paulo 29
Rome 24
Shanghai 23
Assago 16
Naples 16
Mexico City 15
Chennai 14
Curitiba 13
Orem 13
Helsinki 11
Toronto 11
Belo Horizonte 10
Chicago 10
Guayaquil 10
Montreal 10
London 9
Nuremberg 9
Rio de Janeiro 9
Warsaw 9
Dhaka 8
Haiphong 8
Hải Dương 8
Jakarta 8
Tongling 8
Ankara 7
Biên Hòa 7
Brasília 7
Charlotte 7
Porto Alegre 7
Quito 7
Seattle 7
Tokyo 7
Vienna 7
Baghdad 6
Chengdu 6
Denver 6
Houston 6
Montevideo 6
Pasadena 6
Stockholm 6
Turin 6
Atlanta 5
Bologna 5
Brooklyn 5
Can Tho 5
Genoa 5
Goiânia 5
Hillsboro 5
Johannesburg 5
Manaus 5
Paris 5
Philadelphia 5
Reston 5
Ribeirão Preto 5
Alexandria 4
Bogotá 4
Boston 4
Calgary 4
Camden 4
Campinas 4
Da Nang 4
Delhi 4
Frankfurt am Main 4
Ha Long 4
Istanbul 4
Kingston 4
Kuala Lumpur 4
Las Vegas 4
Lấp Vò 4
Mumbai 4
Phoenix 4
San Francisco 4
Santiago 4
São José dos Campos 4
Astana 3
Cairo 3
Camaçari 3
Casablanca 3
Charleston 3
Des Moines 3
Doha 3
Dubai 3
Florence 3
Guarulhos 3
Hangzhou 3
Joinville 3
Totale 2.707
Salva come PNG Salva come JPEG
Nome #
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life 431
A new prognostic and predictive tool for shared decision making in stage III colon cancer 103
Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis 98
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials 90
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy 89
Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: a 10-year experience in a single Italian Cancer Center 88
Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancers 86
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 81
Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer 78
BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer 72
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 69
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study 67
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets 66
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients 66
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial 65
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer 63
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 63
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy 62
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma 61
Microsatellite-Instability-High Advanced Colorectal Cancer 59
Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting 58
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors 58
The impact of ARID1A mutation on molecular characteristics in colorectal cancer 57
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 56
Colorectal cancer: epigenetic alterations and their clinical implications 56
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention 56
Fertility Preservation Practices and Gastrointestinal (GI) Oncologist in Europe: A Pan-European study 51
New perspectives for colorectal cancer 51
Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer 50
A polymorphism within the Vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/ bevacizumab or FOLFIRI/Cetuximab 50
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer 49
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis 49
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? 48
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective 48
Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study 48
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study 48
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients 48
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset 47
Molecular profile of BRCA-mutated biliary tract cancers 46
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) 45
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype 45
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer 45
Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 45
Redefining Colorectal Cancer by Tumor Biology 44
Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study 44
B cell and B cell-related pathways for novel cancer treatments 44
What We Know About Stage II and III Colon Cancer: It's Still Not Enough 43
Cisplatin-related Atrial Fibrillation during PEB Chemotherapy for Testicular Seminoma: A Case Report 43
Young Patients with Colorectal Cancer: Risk, Screening, and Treatment 43
Management of Advanced Small Bowel Cancer 42
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) 42
The role of tumor angiogenesis as a therapeutic target in colorectal cancer 41
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy 41
Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey 41
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? 41
Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients 41
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers 40
From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancer 40
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study 40
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma 38
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets 38
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies 38
Outlooks on Epstein-Barr virus associated gastric cancer 38
Metastatic sarcoma: tailored strategies for a heterogeneous disease 38
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions 37
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care? 37
Safety and Tolerability of c-MET Inhibitors in Cancer 35
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 35
Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer 35
The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer 35
Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives 33
The urgent need to improve the tools to assess clinical benefit and value of cancer treatment 33
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives 32
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? 32
Molecular Variances Between Right- and Left-sided Colon Cancers 31
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients 31
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors 31
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers 31
The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives 31
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients 31
Maintenance Olaparib for Metastatic Pancreatic Cancer 31
Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens 30
Universal tumor screening and mainstream genetic testing for Lynch syndrome in colorectal cancer: a scoping review of barriers and facilitators 28
Routinely Updating Patients With Cancer About Variant of Uncertain Significance Reclassifications: A Premature Responsibility for Community Oncologists 28
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 27
Reliability of patient-reported toxicities during adjuvant chemotherapy 26
Practice-changing updates in the adjuvant and metastatic setting 26
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system 24
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials 24
Circulating tumour DNA in oligometastatic oesophago-gastric cancers: applications, challenges, and future directions 9
Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy 9
Knowledge and resources gaps for adolescent and young adult (AYA) cancer patients: Results from survAYA, an Italian National Survey 5
Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer 5
Absence of co-occurrence between HER2 amplification and dMMR/MSI in a large multicentric colorectal cancer cohort 3
Totale 4.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.580
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 4 4 4
2024/2025793 1 2 1 4 1 123 79 109 74 182 75 142
2025/20263.647 362 228 546 389 91 158 585 208 283 233 202 362
2026/2027224 192 32 0 0 0 0 0 0 0 0 0 0
Totale 4.676